Member Info for KingHomerJ

How has Suzy dodged this one…..her role needs to be up there for a vote aswell…… maybe she knows the other three and has oceatrated the whole thing….. more time more money rinsed - smoke and mirrors - absolute scammers

I think this is automatic info sent out by the Investors meet company platform... to do these types of calls / presentations presumably they will have to book a slot and pay for this service

I note there is inconsistencies within the RNS - the last two are very different in the "About Physiomics Jazz" at the bottom.

I also note that why has the latest RNS got a "Question Mark ? " after virtual Tumour and CRUK has been droppped?

if this is merely a mistake then the attention to detail !!!!

RNS 1st March 2024

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour? technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

RNS 19th February 2024

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

Interims will be next week I think.

Going wild another 33 lol

Needs to be questioned….

BOD of directors all used to work for the same company.

Val Lab PYC has an agreement with

Scientific Advisory Board Together.

All seems like they getting tighter…. VAL has been decimated (so have we mind) but doesn't give a good vibe

Was Global Senior Vice President and Head of Capital Solutions for Syneos Health

Syneos is where Dr Peter Sagenent and Dr Kumar used to work….

The relationship seems to be getting closer which I’m

Not sure is a good thing….

PYC needs to stay away from Val in my eyes……

Jim also stated that there would be an RNS about meeting / exceeding or not exceeding expectations???

There is zero volume - no one is interested- my concern is even a few more contracts and the price won’t move.

I’m not sure the BOD have an understanding of The market and also creating value for all.

I mean when did they last buy shares / exercise on options….

There is literally zero interest- not even people picking stock up at these lows. Volume is pretty much zero which is awful tbh

Even with a few new contracts what’s it going to do move to 1.60 then float back down again. The past two minimal contracts set it south.

Well there suppose to be a Investors meet company meeting next month as per previous announcement- obvs if there’s no further updates then the BOD will be shot to pieces after stating (contracts watch this space etc)

Let’s hope we get some contracts and it’s not just a load of BS like the BOD at VAL

I believe it a license you pay for annually, anywhere between 2-5k

The trial with beyond blood is a two year trial minimum…. So years down the line….

No I am still heavily invested however I have the right to question the facts of matter which are facts and point that the BOD have failed us in recent years.

Also they talk about 5 contracts pretty much on pen to paper and another x in discussion.

If those 5 contracts aren’t signed and converted then the BOD will look like fools again as they are talking about “potential contacts in the future” effectively all these “potentials” already look priced in….

Realistic this is going to be a long long way back to any for of recovery IN MY OPINION…

I’ll just leave this now, as clearly people don’t like a Factual opinion.

I think the prostate cancer dosing app is what’s killed this…. Basically stating it’s years down the line…..after previously stating Dosemerx was a route to comersalisation

Not sure there was a dozen there was 5 I believe that we’re pretty much over the line but the rest where tentative.

Concern for me is that contracts are being won and it’s not shifting the SP as frankly the BOD are disinterested in MC, Market Value, Shareholders dialog and current performance.

And you can bet your bottoms dollar the next RNS that comes which is a contract will have zero value attached to it ….therefore won’t move the SP again - could be AZN and it still wouldn’t make a difference

Kinda valid point though

Think they need to understand the market and understand there obligation to shareholders.

This RNS (REACH) news has sent the SP down.

There needs to be a material RNS very soon or this will slowly drift.

I think the board definition of performance and everyone else’s is very different.

And I would urge shareholders to contact the company / Peter and voice your concerns as I will

They also mentioned a business update in March so to cement there pipeline as mentioned they will need to secure a hand full of new contracts very soon

If you have his email? i have always emailed JM

but on the other hand - pretty sure share holders shouldn't have to correct the BOD about things that they have actively said in the public domain and not followed through ?

Personally I do think this is clutching at straws... id love to be corrected.

What we need for starters is the BOD to actually provide and engage with the shareholders like they state numerous times in presentations but never seem to deliver.